mProX™ Human SRPK1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX494	Magic™ Human SRPK1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;MDA-MB-231;MDA-MB-417.5

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Denys-Drash Syndrome; Lung Cancer

Gene ID

Human:6732

UniProt ID

Human:Q96SB4

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SRPK1 is a protein kinase that has been implicated in various biological processes and diseases, including endocrine cancers, ovarian cancer, male gametogenesis, and Alzheimer's disease. In endocrine cancers, SRPK1 has been identified as a potential biomarker and therapeutic target, as it is involved in the regulation of PI3KŒ¥ isoforms and AKT/mTOR signaling. In ovarian cancer, SRPK1 is one of the biomarkers that are sensitive to platinum-based chemotherapy and can be used in immunotherapy. In male gametogenesis, SRPK1 is critical for the partitioning of nuclei in the formation of male gametes. In Alzheimer's disease, SRPK1 regulates the splicing of VEGF isoforms, which have differential protective effects against neurotoxic events associated with the disease. Overall, SRPK1 has diverse applications in different diseases and biological processes, making it a potential target for therapeutic interventions.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SRPK1 Stable Cell Line (S01YF-1023-PY105). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Smith (Verified Customer)

How does SRPK1 regulate angiogenesis in endothelial cells? May 09 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

SRPK1 is part of a network that controls VEGFR1 alternative splicing in endothelial cells, promoting angiogenesis and potentially contributing to lung tumor progression. May 09 2021

chat Peyton Smith (Verified Customer)

What is the role of SRPK1 in colon adenocarcinoma? Mar 10 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

SRPK1, along with PP1α, modulates SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma, affecting tumor progression. Mar 10 2020

Published Data

Fig.1 Cell migration is impeded when SRPK1 is knocked down in ER-negative human breast cancer cells.

Random cell migration of MDA-MB-231 and -417.5 cells was hindered by a transient knockdown, as evidenced by a significant inhibition (2-tailed t test, **P < 0.01).

Ref: Van Roosmalen, Wies, et al. "Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant." The Journal of clinical investigation 125.4 (2015): 1648-1664.

Pubmed: 25774502

DOI: 10.1172/JCI74440

Research Highlights

Ha, Siyoung. et al. "Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers." Frontiers in endocrinology, 2023.
The PI3K/AKT signaling pathway exhibits upregulation in various cancer types, particularly involving PI3Kδ among class I PI3K isoforms. Alternative mRNA splicing is emerging as a crucial mechanism in cancer development. The research focused on PIK3CD-S, an oncogenic splice variant that contributes to tumor aggressiveness and drug resistance in prostate cancer. Comprehensive analyses in patient samples and cell lines from endocrine/solid tumors demonstrated high PI3Kδ isoform expression. Differential profiles of PIK3CD-S/PIK3CD-L were observed, impacting AKT/mTOR signaling in multiple cancer cell lines. PTEN negatively regulates PI3Kδ-L, while PI3Kδ-S remains unaffected. Inhibitors Idelalisib and SRPIN340 showed efficacy in targeting PI3Kδ-expressing tumors, with a synergistic effect observed with their combination, offering potential for PI3Kδ-S as a prognostic biomarker and drug target in advanced endocrine cancers.
Ha, Siyoung. et al. "Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers." Frontiers in endocrinology, 2023.
Pubmed: 37670888 DOI: 10.3389/fendo.2023.1190479

Liu, Jiao. et al. "Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer." Translational oncology, 2023.
This study sought to identify biomarkers sensitive to platinum-based chemotherapeutic agents for use in immunotherapy in patients with ovarian cancer (OC). The implications of these biomarkers' mechanisms of action were also investigated. OC is a highly lethal gynecological malignancy, making the search for effective treatment strategies crucial. This research contributes to the understanding and potential improvement of OC treatment outcomes through the identification and examination of relevant biomarkers.
Liu, Jiao. et al. "Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer." Translational oncology, 2023.
Pubmed: 37619523 DOI: 10.1016/j.tranon.2023.101762